|
|
|
إصدار جديد "كتاب "ارتفاع ضغط الدم: حقائق وخرافات الكتاب متوفر في مكتبات جرير في الخليج
ومكتبة سمرقند في قطر (خدمة التوصيل) |
What is new in Endocrinology?
1) Tirzepatide for the treatment of obesity.
Weekly subcutaneous Tirzepatide, a dual GLP-1 receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) agonist, led to a mean reduction in weight of 15% with 5 mg doses, 19.5% with 10 mg doses, and 20.9% with 15 mg doses.
Jastreboff A, et al. New England Journal of Medicine 2022;387(3):205-216
2) Dulaglutide for pediatric type 2 diabetes.
Treatment with dulaglutide was effective in improving glycemic control among youths with type 2 diabetes who were being treated with or without metformin or basal insulin, without an effect on BMI.
Arslanian S, et al. New England Journal of Medicine 2022;387(5):433-443.
3) Prolonged use of PPI is associated with increased risk of type 2 diabetes.
Compared with patients who used PPIs for <8 weeks, higher odds of diabetes of 19%, 43%, and 56% were observed among those who used PPIs for between 8 weeks and 6 months, 6 months and 2 years, and >2 years, respectively.
Ciardullo S, et al. J Clinical Endocrinology & Metabolism 2022;107(7):e2671-e2679.
4) FDA approves the first smart insulin pen system to help with dosing.
5) Do not routinely test for vitamin D.
Routine testing for vitamin D levels in asymptomatic individuals is not recommended, based on a lack of evidence for benefit.
McChesney C, et al. British Medical Journal 2022;378:e070270
Weekly subcutaneous Tirzepatide, a dual GLP-1 receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) agonist, led to a mean reduction in weight of 15% with 5 mg doses, 19.5% with 10 mg doses, and 20.9% with 15 mg doses.
Jastreboff A, et al. New England Journal of Medicine 2022;387(3):205-216
2) Dulaglutide for pediatric type 2 diabetes.
Treatment with dulaglutide was effective in improving glycemic control among youths with type 2 diabetes who were being treated with or without metformin or basal insulin, without an effect on BMI.
Arslanian S, et al. New England Journal of Medicine 2022;387(5):433-443.
3) Prolonged use of PPI is associated with increased risk of type 2 diabetes.
Compared with patients who used PPIs for <8 weeks, higher odds of diabetes of 19%, 43%, and 56% were observed among those who used PPIs for between 8 weeks and 6 months, 6 months and 2 years, and >2 years, respectively.
Ciardullo S, et al. J Clinical Endocrinology & Metabolism 2022;107(7):e2671-e2679.
4) FDA approves the first smart insulin pen system to help with dosing.
5) Do not routinely test for vitamin D.
Routine testing for vitamin D levels in asymptomatic individuals is not recommended, based on a lack of evidence for benefit.
McChesney C, et al. British Medical Journal 2022;378:e070270